Literature DB >> 21067862

Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells.

Yukihiro Akao1, Shunsuke Noguchi, Akio Iio, Keitaro Kojima, Takeshi Takagi, Tomoki Naoe.   

Abstract

MiR-34a was identified as one of the down-regulated micro-RNAs (miRs) in human colorectal cancer 5-fluorouracil (5-FU)-resistant DLD-1 cells compared with those in the parental DLD-1 cells. Exposure to 5-FU at 30 μM activated phosphoinositide 3-kinase (PI3K)/Akt signaling markedly from 12h up to 48 h in the 5-FU-resistant cells compared with that in the parental cells and resulted in an overt difference in growth at those times. Furthermore, the expression of miR-34a in the 5-FU-resistant cells was sustained at a low-level, whereas it was up-regulated in the parental cells after the 5-FU treatment. Sirt1, which is one of the target genes for miR-34a and related to drug-resistance, was strikingly up-regulated in the 5-FU-resistant cells. The ectopic expression of miR-34a in the 5-FU-resistant cells inhibited growth, as in the parental cells, and attenuated the resistance to 5-FU through the down-regulation of Sirt1 and E2F3. Moreover, the silencing of Sirt1 significantly canceled the resistance to 5-FU in the 5-FU-resistant cells. These findings suggest that miR-34a targeting the Sirt1 and E2F3 genes could negatively regulate, at least in part, the resistance to 5-FU in human colorectal cancer DLD-1 cells.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21067862     DOI: 10.1016/j.canlet.2010.10.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  88 in total

Review 1.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

2.  Histone/protein deacetylase SIRT1 is an anticancer therapeutic target.

Authors:  Bor-Jang Hwang; Amrita Madabushi; Jin Jin; Shiou-Yuh S Lin; A-Lien Lu
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

Review 3.  Advances in epigenetic biomarker research in colorectal cancer.

Authors:  Xi Wang; Ye-Ye Kuang; Xiao-Tong Hu
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer.

Authors:  Mehdi Manoochehri; Ashraf Karbasi; Mojgan Bandehpour; Bahram Kazemi
Journal:  Pathol Oncol Res       Date:  2013-10-14       Impact factor: 3.201

5.  Upregulated miR-193a-3p as an oncogene in esophageal squamous cell carcinoma regulating cellular proliferation, migration and apoptosis.

Authors:  Yunfeng Yi; Jianming Chen; Changjie Jiao; Jing Zhong; Zhiming Song; Xiaoping Yu; Xiujuan Lu; Baoli Lin
Journal:  Oncol Lett       Date:  2016-10-05       Impact factor: 2.967

Review 6.  MicroRNAs and DNA damage response: implications for cancer therapy.

Authors:  Yemin Wang; Toshi Taniguchi
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

7.  The dual role of sirtuins in cancer.

Authors:  Laia Bosch-Presegué; Alejandro Vaquero
Journal:  Genes Cancer       Date:  2011-06

8.  microRNA-34a promotes DNA damage and mitotic catastrophe.

Authors:  Alexander V Kofman; Jungeun Kim; So Yeon Park; Evan Dupart; Christopher Letson; Yongde Bao; Kai Ding; Quan Chen; David Schiff; James Larner; Roger Abounader
Journal:  Cell Cycle       Date:  2013-09-19       Impact factor: 4.534

Review 9.  The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.

Authors:  Brian D Adams; Christine Parsons; Frank J Slack
Journal:  Expert Opin Ther Targets       Date:  2015-12-11       Impact factor: 6.902

Review 10.  Colon cancer stem cells: controversies and perspectives.

Authors:  Maria Ausiliatrice Puglisi; Valentina Tesori; Wanda Lattanzi; Giovanni Battista Gasbarrini; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.